A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
1996

Maximum Tolerated Dose of Gemcitabine in Lung Cancer

Sample size: 24 publication Evidence: low

Author Information

Author(s): H Anderson, N Thatcher, J Walling, H Hansen

Primary Institution: University of Manchester, Christie Hospital and Wythenshawe Hospital

Hypothesis

What is the maximum tolerated dose and toxicity of gemcitabine when given as a 24-hour infusion to patients with inoperable non-small-cell lung cancer?

Conclusion

The maximum tolerated dose of gemcitabine given as a 24-hour infusion was found to be 180 mg/m², with neutropenia and lethargy as the main toxicities.

Supporting Evidence

  • Partial response was observed in five (21%) patients lasting 10 to 51 weeks.
  • The main toxicity was neutropenia and lethargy.
  • Neutropenia was short-lived and manageable.

Takeaway

Doctors wanted to find out how much gemcitabine medicine can be safely given to people with a type of lung cancer. They found that 180 mg is the most they can give without causing too many problems.

Methodology

Patients received gemcitabine as a 24-hour infusion on days 0, 7, and 14, with courses repeated every 28 days, and the study assessed maximum tolerated dose and toxicity.

Limitations

The study involved only 24 patients, which may limit the generalizability of the findings.

Participant Demographics

16 males and 8 females with a median age of 51 years.

Statistical Information

Confidence Interval

95% CI 7-42%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication